Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?

Front Immunol. 2022 Sep 13:13:1017924. doi: 10.3389/fimmu.2022.1017924. eCollection 2022.

Authors

Chilam Chan¹, Marta Lustig², Niklas Baumann², Thomas Valerius², Geert van Tetering¹, Jeanette H W Leusen¹

Affiliations

¹ Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands.
² Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.932155.].

Keywords: CD47-SIRPalpha axis; IgA; antibodies; cancer immonotherapy; immune checkpoint; macrophages; myeloid checkpoints; neutrophils (PMNs).

Copyright © 2022 Chan, Lustig, Baumann, Valerius, van Tetering and Leusen.

Publication types

Published Erratum